Pricing Log in Create free account

Cellectis S.A. (CLLS) vs Telomir Pharmaceuticals, Inc. (TELO)

Cellectis S.A. and Telomir Pharmaceuticals, Inc. are both Biotechnology companies. Cellectis S.A. and Telomir Pharmaceuticals, Inc. are of similar size ($79.9M and $77.3M). Telomir Pharmaceuticals, Inc. has the higher net margin (0.00% vs −102.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Telomir Pharmaceuticals, Inc. leads on 8 and Cellectis S.A. on 4.

Valuation

Metric CLLS TELO Biotechnology median
P/E n/m n/m 8.50
P/S 1.64 n/m 9.71
P/B 2.55 12.81 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 0.18 n/m 9.21
Earnings yield (62.89%) (85.85%) (33.15%)
Free cash flow yield (44.14%) (7.62%) (25.50%)

Profitability

Metric CLLS TELO Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (90.88%) 0.00% 0.00%
Net margin (102.34%) 0.00% 0.00%
Free cash flow margin (68.63%) 0.00% 0.00%
Return on equity (94.54%) (1,885.50%) (56.36%)
Return on assets (21.02%) (1,678.31%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CLLS TELO Biotechnology median
Revenue growth (TTM) 0.61% — 6.02%
EPS growth (last fiscal year) (63.41%) 41.07% 30.26%
Revenue growth, 5-year CAGR (0.70%) — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric CLLS TELO Biotechnology median
Debt to equity 1.79 0.03 0.00
Current ratio 1.37 16.14 4.72
Net debt to EBITDA 9.54 0.69 0.96

Dividend

Metric CLLS TELO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CLLS TELO Biotechnology median
Market cap 79.92m 77.30m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack